These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7981511)

  • 1. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol.
    Runge VM; Wells JW; Nelson KL; Linville PM
    J Magn Reson Imaging; 1994; 4(5):669-73. PubMed ID: 7981511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
    Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
    Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
    Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
    AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose gadoteridol in MR imaging of intracranial neoplasms.
    Runge VM; Kirsch JE; Burke VJ; Price AC; Nelson KL; Thomas GS; Dean BL; Lee C
    J Magn Reson Imaging; 1992; 2(1):9-18. PubMed ID: 1623287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients.
    Kuhn MJ; Hammer GM; Swenson LC; Youssef HT; Gleason TJ
    Comput Med Imaging Graph; 1994; 18(5):391-9. PubMed ID: 7954317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases.
    Yuh WT; Engelken JD; Muhonen MG; Mayr NA; Fisher DJ; Ehrhardt JC
    AJNR Am J Neuroradiol; 1992; 13(1):335-45. PubMed ID: 1595472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
    Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
    Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Aug; 31(8):472-8. PubMed ID: 8854193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consecutive acquisition of time-resolved contrast-enhanced MR angiography and perfusion MR imaging with added dose of gadolinium-based contrast agent aids diagnosis of suspected brain metastasis.
    Tsuchiya K; Aoki S; Shimoji K; Mori H; Kunimatsu A
    Magn Reson Med Sci; 2013; 12(2):87-93. PubMed ID: 23666159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.
    Yuh WT; Fisher DJ; Engelken JD; Greene GM; Sato Y; Ryals TJ; Crain MR; Ehrhardt JC
    Radiology; 1991 Aug; 180(2):485-91. PubMed ID: 2068317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
    Maravilla KR; Smith MP; Vymazal J; Goyal M; Herman M; Baima JJ; Babbel R; Vaneckova M; Žižka J; Colosimo C; Urbańczyk-Zawadzka M; Mechl M; Bag AK; Bastianello S; Bueltmann E; Hirai T; Frattini T; Kirchin MA; Pirovano G
    AJNR Am J Neuroradiol; 2015 Jan; 36(1):14-23. PubMed ID: 25300984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
    Carvlin MJ; De Simone DN; Meeks MJ
    Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain metastases--comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging.
    Akeson P; Larsson EM; Kristoffersen DT; Jonsson E; Holtås S
    Acta Radiol; 1995 May; 36(3):300-6. PubMed ID: 7742127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1994 Dec; 29(12):1050-6. PubMed ID: 7721546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detectability of small liver metastases with gadolinium BOPTA.
    Runge VM; Lee C; Williams NM
    Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of standard and high-dose contrast-enhanced breath-hold liver magnetic resonance for visualization of metastatic disease in an animal model.
    Runge VM
    Invest Radiol; 1998 May; 33(5):263-7. PubMed ID: 9609484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis.
    Yuh WT; Tali ET; Nguyen HD; Simonson TM; Mayr NA; Fisher DJ
    AJNR Am J Neuroradiol; 1995 Feb; 16(2):373-80. PubMed ID: 7726087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material.
    Runge VM; Kirsch JE; Wells JW; Dunworth JN; Woolfolk CE
    AJR Am J Roentgenol; 1994 Feb; 162(2):431-5. PubMed ID: 8310940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadoteridol in multiple sclerosis patients. A comparison of single and triple dose with immediate vs. delayed imaging.
    Wolansky LJ; Finden SG; Chang R; Conigliari M; Lee HJ; Shaderowsky PD; Cook SD
    Clin Imaging; 1998; 22(6):385-92. PubMed ID: 9876905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain.
    Runge VM; Parker JR; Donovan M
    Invest Radiol; 2002 May; 37(5):269-80. PubMed ID: 11979153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.